Neuland Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 24-Jul-2026.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported strong FY2025-26 results with revenue from operations growing 37% to Rs 2,02,299 lakhs from Rs 1,47,684 lakhs. Consolidated profit after tax jumped nearly 40% to Rs 36,400 lakhs, while EBITDA margin expanded from 22.6% to 28.6%. The board recommended a final dividend of Rs 34 per share (340%) with record date July 24, 2026. Key developments include appointment of Dr. Mauricio Futran as Additional Director and approval for capacity expansion at Unit 1 with an investment of Rs 143.4 crores to meet growing customer demand. The statutory auditors issued unmodified opinions on both standalone and consolidated financial statements.
The company delivered robust double-digit revenue and profit growth with improving margins, signaling strong operational performance. The dividend announcement and capacity expansion plan indicate confidence in future growth prospects, which should be positive for shareholder returns.